Payment overview · 2025
General Payments
$136.36
7 reported records · 7 companies
Healthcare provider profile · identity verified
Michael A Patterson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · IMPERIAL, MO · NPI 1699857151
Verified facts
What the public records show
CMS Open Payments records show Michael A Patterson, D.O. received $136.36 in general payments during 2025 across 7 reported records.
Sumitomo Pharma America, Inc. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Edarbyclor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.09 | 18.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.28 | 17.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.94 | 16.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.21 | 15.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.88 | 12.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.33 | 10.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 10.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.36 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 510 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 337 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 251 | 41 |
| Lisinopril | Lisinopril | 246 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 56 |
| Omeprazole | Omeprazole | 191 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 55 |
| Gabapentin | Gabapentin | 186 | 38 |
| Meloxicam | Meloxicam | 184 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 169 | 43 |
| Metformin Hcl | Metformin Hcl | 157 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 39 |
| Losartan Potassium | Losartan Potassium | 146 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 39 |
| Temazepam | Temazepam | 117 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 26 |
| Simvastatin | Simvastatin | 104 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 103 | 11 |
| Trazodone Hcl | Trazodone Hcl | 99 | 26 |
| Furosemide | Furosemide | 97 | 24 |
| Methylprednisolone | Methylprednisolone | 93 | 65 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 15 |
| Diazepam | Diazepam | 90 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 81 | 16 |
| Tramadol Hcl | Tramadol Hcl | 79 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 21 |
| Sertraline Hcl | Sertraline Hcl | 76 | 23 |
| Lorazepam | Lorazepam | 72 | 16 |
| Prednisone | Prednisone | 72 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 65 | 14 |
| Ozempic | Semaglutide | 62 | 12 |
| Allopurinol | Allopurinol | 60 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | suppressed |
| Glipizide Er | Glipizide | 57 | 12 |
| Buspirone Hcl | Buspirone Hcl | 54 | 11 |
| Glipizide | Glipizide | 54 | 11 |
| Ibuprofen | Ibuprofen | 52 | 13 |
| Clonazepam | Clonazepam | 51 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 15 |
| Risperidone | Risperidone | 45 | suppressed |
| Azithromycin | Azithromycin | 43 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 13 |
| Atenolol | Atenolol | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 13 |
| Finasteride | Finasteride | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Famotidine | Famotidine | 37 | 12 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Nabumetone | Nabumetone | 32 | suppressed |
| Eliquis | Apixaban | 31 | 12 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Carvedilol | Carvedilol | 30 | 12 |
| Lovastatin | Lovastatin | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 18 |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.36 · 7 records | Sumitomo Pharma America, Inc. | AZMIRO, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, OTEZLA, REPATHA, VRAYLAR, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error